OncoMatch/Clinical Trials/NCT06688188

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

Is NCT06688188 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-JH12 for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06688188Data as of May 2026

Treatment: 68Ga-JH12 — 68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify